Graft-versus-host disease (GVHD) due to host-reactive antigenic differences between HLA-identical pairs remains an important cause of morbidity and mortality after allogeneic transplantation. The helper T-lymphocyte precursor (HTLp) assay, using peripheral blood mononuclear cells (PBMCs), has been variably shown to detect such host-reactive differences. We assessed whether using dendritic cells (DCs) as the stimulator cells would improve the ability of the HTLp assay to detect these differences. We used PBMCs (standard HTLp assay) or monocytederived DCs (DC-HTLp assay) as the stimulator cells for 12 HLA-identical sibling pairs undergoing allogeneic peripheral blood stem cell transplantation. HTLp frequencies were greater by the DC-HTLp assay (median 1:77 712 vs 1:727 514; P ¼ 0.008). The standard HTLp assay did not predict for acute GVHD (P ¼ 0.42), whereas a trend was noted for the DC-HTLp assay (P ¼ 0.095). Of note, of seven patients developing moderately severe to severe acute GVHD, four had a significantly greater DCHTLp frequency compared to the standard HTLp frequency, whereas all four patients who developed no to moderate acute GVHD had similar HTLp frequencies whether PBMCs or DCs were used as the stimulator cells. Although the small number of donor/recipient pairs assessed limits the strength of any conclusions, our study suggests that the DC-HTLp assay is better able to detect clinically significant host-reactive antigenic differences between HLA-identical siblings.
GVHD
Currently, there is no absolutely reliable way to predict for the development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. The degree of HLA matching of the donor and recipient is of crucial importance, but some recipients of HLA-identical sibling stem cells develop significant GVHD. As no association between HLA and the risk of acute GVHD after HLAidentical marrow transplantation has been identified, 1 it appears likely that the development of GVHD in such situations is due to minor histocompatibility antigen (mHA) differences between the donor and recipient. 2 On the other hand, some recipients of stem cells with known HLA mismatches do not develop GVHD for reasons that are poorly understood. 3 Assays with the ability to detect mHA or known HLA mismatches that are destined to initiate clinically significant GVHD would be of major clinical importance. A variety of functional assays have been shown to be of variable ability in predicting GVHD. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] More recently, cytokine gene polymorphisms have been shown to predict for some of the previously unexplained occurrence and severity of GVHD after stem cell transplantation. [20] [21] [22] [23] Previously, others and we have shown that the helper T-lymphocyte precursor (HTLp) assay can predict for the occurrence and severity of acute GVHD after bone marrow transplantation (BMT), although not all investigators have confirmed these results. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In contrast, more recently we have shown that the HTLp assay did not predict for GVHD in donor/recipient pairs undergoing peripheral blood stem cell transplantation (PBSCT). 24 Hence, the ability of the HTLp assay to predict for GVHD may depend on the source of the stem cells.
Dendritic cells (DCs) are the most potent antigenpresenting cells known, and are crucial for the development of naı¨ve immune responses. 25 In addition, Mutis et al 26 have shown that DCs retrovirally transduced with DNA coding for the mHA, HA-1, can rapidly and efficiently induce HA-1-reactive T cells in vitro. We wished to test the hypothesis that using DCs as the stimulator cells instead of peripheral blood mononuclear cells (PBMCs) in the HTLp assay would improve the ability of this assay to detect clinically significant host-reactive antigenic differences (probably non-HLA and possibly mHA) between HLAidentical donor/recipient pairs undergoing PBSCT.
Materials and methods

Samples
Heparinized peripheral blood was collected from healthy volunteers for the mixed lymphocyte reaction (MLR), mixed DC-lymphocyte reaction (MDCLR), and the interleukin (IL) 2 MLR and IL 2 MDCLR assays. The PBMCs were isolated by density-gradient centrifugation, washed and a portion was used to generate fresh DCs, whereas the remainder was cryopreserved until needed. Plasma was filtered, heat inactivated and stored at À701C until required.
Heparinized peripheral blood for the standard HTLp and DC-HTLp assays was collected from the patient prior to PBSCT, and from the donor prior to granulocytecolony-stimulating factor (G-CSF) administration and PBSC harvesting. The PBMCs were isolated by densitygradient centrifugation, washed and cryopreserved until needed.
Generation of DCs
All cell culture and dilutions were performed using RPMI-1640 (ICN Biomedicals Australasia, Sydney, NSW, Australia) plus 10% plasma autologous to the stimulator cells (complete medium). DCs were generated using the method of Romani et al. 27 PBMCs from the recipient were used fresh (MDCLR and IL 2 MDCLR) or thawed (DC-HTLp), washed 3 Â with phosphate-buffered saline (PBS), counted and resuspended at 5 Â 10 6 cells/ml. The cells were incubated at 10 Â 10 6 cells per well in 12-well plates (Linbro, ICN Biomedicals Australasia, Sydney, NSW, Australia) for 2 h at 371C in 95% air/5% CO 2 , after which the nonadherent layer was removed. The adherent layer was carefully washed with PBS, incubated in 2 ml per well of complete medium supplemented with 100 ng/ml of granulocyte-macrophage colony-stimulating factor (ScheringPlough, Baulkham Hills, NSW, Australia) and 1000 U/ml of interleukin 4 (IL 4) (R and D Systems Inc., Minneapolis, MN, USA) for 7 days at 371C in 95% air/5% CO 2 . Tumor necrosis factor-alpha (TNF-a) (Sigma, St Louis, MS, USA) at 10 ng/ml was added for the final 2 days of culture to mature the DCs. The cultured cells were harvested and used immediately as the stimulator cells in the DC-HTLp assay. The average yield of DCs was approximately 5% of the starting number of PBMCs.
Flow cytometry
For flow cytometry, we used conjugated monoclonal antibodies to the following antigens: HLA-DR, CD80 (markers for DCs), and CD2, CD4, CD8, CD14, CD20 and CD33 (lineage markers). All monoclonal antibodies were obtained from BD Biosciences, Scoresby, NSW, Australia. DCs were defined as lineage negative and positive for HLA-DR and CD80. DCs were analyzed immediately on harvesting after the 7-day culture. The DCs were adjusted to 1 Â 10 6 cells in 100 ml of FACS buffer (1% fetal bovine serum in PBS). A measure of 10 ml of the appropriate antibody was added and the cells incubated for 20 min at 41C in the dark. Cells were then washed in FACS buffer, resuspended in a final volume of 50 ml and analyzed using an FACScan (BD Biosciences, Scoresby, NSW, Australia).
Proliferative MDCLR and MLR
DCs or thawed PBMCs were used as the stimulator cells. All cells were resuspended in complete medium. The stimulator cells were irradiated (30 Gy) in a Gammacell 1000 (caesium-137 source, Nordion International Ltd, Ontario, Canada). The MDCLR was set up in 96-well Ubottom microtiter plates (Linbro, ICN Biomedicals Australasia, Sydney, NSW, Australia). Six stimulator cell concentrations were produced by doubling dilutions from 1 Â 10 5 to 3125 cells in 100 ml per well. Responder PBMCs from an HLA-mismatched unrelated individual, at 1 Â 10 5 cells in 100 ml of complete medium, were added to each well. Negative controls included complete medium alone, responder PBMCs alone and the top (1 Â 10 5 cells per well) dilution of the stimulator PBMCs or DCs alone. Positive controls consisted of third and fourth party HLAmismatched PBMCs set up against the responder cells and stimulator cells, and each other. The plates were incubated for 6 days at 371C in 95% air/5% CO 2 in a humidified incubator. On the evening of day 6, each well was pulsed with 1 mCi of 
Indicator cell line
The murine IL 2-dependent cell line, CTLL-2 28 (ATCC, Rockville, MD, USA), was maintained in RPMI-1640 supplemented with 10% fetal bovine serum (CSL, Melbourne, Victoria, Australia), 2% sodium pyruvate (Sigma-Aldrich, Castle Hill, NSW, Australia) and 20 U/ ml of IL 2 (Boehringer Mannheim Australia, Melbourne, Victoria, Australia). The CTLL-2 cells were passaged as required, usually every 3-4 days with the addition of fresh medium and IL 2. At 16 h prior to use in the IL 2 MLR, IL 2 MDCLR, standard HTLp assay or DCHTLp assay, the CTLL-2 cells were washed and maintained in medium without IL 2. A standard curve was included in every experiment to demonstrate the sensitive dose-dependent response to IL 2 (0-2 U/ml) of the CTLL-2 cells.
IL 2 MDCLR and IL 2 MLR
IL 2 is known to be released by activated T cells, therefore the IL 2 MLR assay looks specifically at alloreactive T-cell responses rather than proliferation in general. This assay used CTLL-2 cells, which proliferate in response to the IL 2 released by the activated T cells in each well. The greater the IL 2 production by the proliferating T cells, the greater the proliferation of the CTLL-2 cells.
Stimulator PBMCs and DCs were irradiated (50 Gy) in a Gammacell 1000 and titrated in six doubling dilutions from 1 Â 10 5 to 3125 cells per well. The higher dose of radiation was used to minimize 'back stimulation', that is, the production of IL 2 by stimulator cells. 29 A minimum of six replicates of each test was aliquoted into the 96-well Ubottom plates for each assay. Responder PBMCs, obtained from healthy HLA-mismatched unrelated individuals, were added at 1 Â 10 5 cells in 50 ml of complete medium to each well containing stimulator cells. Positive and negative controls were the same as those used for the MDCLR and MLR. The plates were incubated for 3 days at 371C (95% air/5% CO 2 ) in a humidified incubator. The IL 2 MDCLR and MLR plates were irradiated with 20 Gy on a linear accelerator (Varian, Palo Alto, CA, USA) to prevent the proliferation of the responder cells but not interfere with the ability of these cells to secrete cytokines. 29 CTLL-2 cells (deprived of IL 2 16 h before the assay) were resuspended in complete medium and added at 2 Â 10 3 cells per well. After 8 h incubation, the plates were pulsed with 1 mCi of 3 H-thymidine per well for 16 h, then harvested and counted as described for the standard MDCLR and MLR. A proliferation index was calculated by taking the median (c.p.m.) of the replicates of the test wells and dividing by the median c.p.m. of the wells containing the responder cells alone.
Patients (Table 1)
Between January 1998 and June 1999, 12 patients and their HLA-identical sibling donors, who subsequently underwent allogeneic PBSCT, had peripheral blood taken for the standard HTLp and DC-HTLp assays. HLA identity was confirmed using standard serological techniques for class I and molecular techniques (SSOP) for class II. HLA-DP compatibility was not assessed.
Standard disease included acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in first complete remission, or nontransformed low-grade nonHodgkin's lymphoma (NHL). Advanced disease included AML or ALL with primary induction failure or beyond first complete remission, or intermediate-grade NHL beyond first remission. All but one patient received total body irradiation (TBI) and cyclophosphamide as pretransplant conditioning chemotherapy, whereas the remaining patient received busulfan and cyclophosphamide. Patients with advanced disease mostly received cyclosporine alone as GVHD prophylaxis, whereas patients with standard risk disease received the combination of cyclosporine and shortcourse methotrexate.
Donors were mobilized with G-CSF (lenograstim, AMRAD Pharmaceuticals, Granville, NSW, Australia) at 10 mg/kg twice per day, and PBSCs were collected by leukapheresis on day 5 (76) of the lenograstim. Leukaphereses were performed until 44 Â 10 6 CD34 þ cells per kilogram of patient body weight had been collected.
Acute GVHD was staged according to the IBMTR index. 30 Briefly, grade I acute GVHD of the skin alone was defined as index A, a maximum of grade III of any organ system was defined as index C, and grade IV of any organ was defined as index D. All other combinations were defined as index B. Chronic GVHD was graded according to Ferrara et al. 31 Patients who were not in complete remission at the time of death were defined as dying of the original hematological disease. All other deaths were defined as due to transplantrelated mortality.
Standard HTLp and DC-HTLp assays
Monocyte-derived DCs were generated from cryopreserved recipient PBMCs as described earlier. The HTLp has been described in detail previously. 15 Briefly, the cryopreserved PBMC from the patient (stimulator) and donor (responder) were thawed, washed and resuspended in complete medium. Experiments were set up in parallel with irradiated recipient PBMCs (standard HTLp assay) or with irradiated recipient DCs (DC-HTLp assay) as the stimulator cells. The number of stimulator cells needed for each assay and the low yield of DCs that we were able to obtain from PBMCs meant that, for practical reasons, we chose to use 1.25 Â 10 4 DCs per well as the stimulator cell number in the DC-HTLp assay. Irradiated (50 Gy) recipient PBMCs at 1 Â 10 5 per well and DCs at 1.25 Â 10 4 in 100 ml per well were cultured with graded numbers of donor responder cells (1, 2, 4, 8 and 10 Â 10 4 per well in 50 ml) with 24 replicates of each dilution in round-bottomed 96-well microtiter plates for 64 h at 371C (95% air/5% CO 2 ). Negative controls were stimulator cells alone and responder cells alone. The positive controls consisted of two PBMC samples from healthy HLA-mismatched unrelated individuals tested against the donor PBMCs, and patient PBMCs and DCs, as well as against each other. The plates were irradiated (20 Gy), and 5 Â 10 3 CTLL-2 cells in 25 ml were added to each well, incubated for a further 8 h and pulsed with 1 mCi of 3 H-thymidine per well. After a further 16 h incubation, the contents of the wells were harvested onto filter mats and the c.p.m. were assessed on a liquid scintillation counter.
Calculation of HTLp frequencies and the number of HTLp infused per kilogram of patient body weight
Microtiter wells were recorded as positive for IL 2 production if 3 H-thymidine incorporation was greater than the mean plus three standard deviations of the control wells. Minimal estimates of HTLp frequencies were obtained according to the Poisson distribution equation as the slope of the line relating to the number of responder cells per well (plotted on the linear x-axis) and the fraction of wells that failed to produce detectable amounts of IL 2 (plotted on the logarithmic y-axis). The slope of the regression line was determined by using the maximum-likelihood analysis method yielding: (i) a minimum frequency estimate; (ii) the 95% confidence limits of this estimate; and (iii) a w 2 estimate of probability (P) for the frequency estimate. In these studies, a P-value of 40.05 indicates that the data conform to the zero-order term of the Poisson equation and that the frequency estimate is statistically acceptable. 32, 33 The number of HTLp infused per kilogram of patient body weight was calculated as follows: (HTLp frequency Â number of mononuclear cells infused)/patient body weight (kg).
Statistical analyses
The comparisons for the MLR and MDCLR, and the IL 2 MLR and IL 2 MDCLR were performed by an analysis of variance using logarithmic-transformed data. The standard HTLp frequencies and the DC-HTLp frequencies were compared using the Spearman correlation coefficient. The relationship between the HTLp frequency and acute GVHD, transplant-related mortality and overall survival, and the relationship between the HTLp number per kilogram of patient body weight infused and acute GVHD, transplant-related mortality and overall survival were assessed by the Mann-Whitney test or the Kruskal-Wallis test. The Wilcoxon signed-rank test was used when comparing acute GVHD indices of the standard HTLp and DC-HTLp assays (SYSTAT 8.0, SPSS Inc., Chicago, IL, USA).
Results
Comparison of DCs and PBMCs as the stimulator cells in the proliferative assays (Figure 1a and b) The DCs derived from monocytes after a 7-day culture strongly expressed HLA-DR and CD80 with minimal expression of CD14 and CD33 (data not shown). The antigen-presenting potency of DCs and PBMCs derived from the same individuals was compared in the proliferative MDCLR and MLR assays (n ¼ 10; Figure 1a ) and the IL 2 MDCLR and IL 2 MLR assays (n ¼ 15; Figure 1b) . The responder PBMCs were obtained from HLA-mismatched unrelated individuals. DCs were significantly more potent in both assays. Hence, we decided to compare the use of DCs and PBMCs as the stimulator cells in the HTLp assay.
Clinical Data (Tables 1 and 2) HTLp assays were performed using PBMCs and DCs derived from the same HLA-identical sibling donor/ recipient pairs (n ¼ 12) who subsequently underwent PBSCT ( Table 1 ). The cell infusion data are listed in Table 1 . The median follow-up of all patients was 455.5 (range 11-1784) days and the median follow-up of survivors was 1770 (range 1294-1784) days (Table 2) .
One patient died before engraftment. The remaining 11 patients were evaluable for acute GVHD. One additional patient died before day 100 leaving 10 patients assessable for chronic GVHD. All patients were assessable for transplant-related mortality, relapse and survival.
HTLp frequencies and acute GVHD (Table 2) The HTLp assays were performed in the GVH direction on 12 HLA-identical sibling donor/recipient pairs ( Table 2 ). The standard HTLp assay did not predict for the index of acute GVHD (Kruskal-Wallis, P ¼ 0.42), although there was a trend suggesting that the DC-HTLp assay may predict for the index of acute GVHD (Kruskal-Wallis, P ¼ 0.095).
In patients with nil to moderate (index 0-B) acute GVHD, there was no difference in HTLp frequencies between the standard HTLp assay and the DC HTLp assay (Wilcoxon, P ¼ 0.66). Although, for patients developing moderately severe to severe (index C-D) acute GVHD, there was a trend for higher HTLp frequencies with the DC-HTLp assay (Wilcoxon, P ¼ 0.12).
HTLp per kilogram and acute GVHD
Using the HTLp per kilogram of recipient body weight gave very similar results to those noted when using the HTLp frequency. The HTLp per kilogram using the standard HTLp assay did not predict for the index of acute GVHD (Kruskal-Wallis, P ¼ 0.98), although there was a trend suggesting that the HTLp per kilogram using the DC-HTLp assay may predict for the index of acute GVHD (Kruskal-Wallis, P ¼ 0.12).
In patients with nil to moderate (index 0-B) acute GVHD, there was no difference in HTLp per kilogram between the standard HTLp assay and the DC-HTLp assay (Wilcoxon, P ¼ 0.27). Similarly, there was no difference between the HTLp per kilogram between the two assays in those patients developing moderately severe to severe (index C-D) acute GVHD (Wilcoxon, P ¼ 0.5).
Standard HTLp vs DC-HTLp frequencies (Figures 2 and 3)
The DC-HTLp frequencies (median: 1 in 77 712) were greater than the standard HTLp frequencies (median: 1 in 727 514) (Figure 2 ; Spearman's correlation coefficient, P ¼ 0.008). All four patients who developed index 0-B acute GVHD had similar HTLp frequencies by both the standard HTLp and DC-HTLp assays, whereas four of the seven patients developing index C-D acute GVHD had a significantly greater DC-HTLp frequency compared to the frequency as assessed by the standard HTLp assay (Figure 3 ). This suggests that using DCs as the stimulator cells may allow improved sensitivity of the HTLp assay to detect clinically significant host-reactive antigenic differences between the donor and recipient.
HTLp frequency and chronic GVHD
In all, 10 patients were evaluable for chronic GVHD. Nine patients developed extensive chronic GVHD and, not surprisingly, neither the standard HTLp assay or the DCHTLp assay proved useful in predicting chronic GVHD.
Outcome
Four patients died from transplant-related complications. There was no difference in the HTLp frequencies between patients who died from transplant-related complications and those who survived the transplant. This applied whether PBMCs (Mann-Whitney, P ¼ 0.32) or DCs (Mann-Whitney, P ¼ 0.39) were used as the stimulator cells. Calculating the frequencies of HTLp cells infused per kilogram did not alter the associations with transplantrelated mortality (Mann-Whitney: PBMCs, P ¼ 0.23; DCs, P ¼ 0.67). The HTLp frequencies did not predict for survival (Mann-Whitney: PBMCs, P ¼ 0.42; DCs, P ¼ 0.39) nor did the number of HTLp infused per kilogram of patient body weight (Mann-Whitney: PBMCs, P ¼ 0.87; DCs, P ¼ 0.31). All relapses (n ¼ 4) occurred in the groups with higher HTLp frequencies.
Discussion
An assay with the ability to predict the clinical significance of histocompatibility antigen differences between donor/ recipient pairs prior to allogeneic transplantation in routine clinical practice would be of considerable value. Transplantation using donors with undetected histocompatibility antigen differences destined to cause severe GVHD may be avoided, or the transplant conditioning therapy and GVHD prophylaxis may be modified to decrease that risk. Alternatively, the presence of known histocompatibility antigen differences that will not cause severe GVHD (permissible mismatches) in a particular donor/recipient pair may allow the transplant to proceed. To date, there have been many attempts, with some success, to develop functional assays capable of such discrimination. The MLR has not proved capable of such discrimination, 4 although perhaps an advance on the MLR is the mixed epidermalcell lymphocyte reaction. 5 The skin-explant assay, where a sample of recipient skin is cultured with donor lymphocytes prior to histological assessment, has proved useful in several centers. 6, 7 It has been the assays based on limiting dilution techniques that have generated the most interest. Kaminski et al 8 were the first to show the clinical usefulness of such assays when they demonstrated that measurement of the frequency of cytotoxic T cells (CTLp) in the PBMC population of the donor capable of recognizing and lysing PBMCs from the bone marrow recipient predicted for the incidence and severity of acute GVHD after unrelated donor BMT. Others have confirmed these results, 11 although some have not been able to confirm the ability of this assay to predict for acute GVHD. 10, 12 This assay does not have the sensitivity to detect host-reactive antigenic differences between HLA-identical sibling donor/ recipient pairs.
The other widely studied limiting dilution assay, the HTLp assay, detects the frequency of IL 2-producing cells in the PBMC population of the donor that are capable of recognizing antigen differences on the PBMCs of the bone marrow recipient. Many groups have shown that this assay can predict for the incidence and severity of acute GVHD, suggesting that this assay is capable of detecting clinically significant host-reactive antigenic differences between HLA-identical sibling donors and recipients [14] [15] [16] [17] [18] [19] and HLA-matched unrelated donors and recipients. 9, 11, 16, 17 Although not all groups were able to confirm these findings. 7, 10, 12, 13 Unfortunately, the statistical success of the HTLp assay has not translated into a routinely useful clinical assay.
Many transplant centers have moved from using bone marrow to using peripheral blood stem cells yet there is, to date, only one report assessing the relationship of the HTLp assay and acute GVHD in donor/recipient pairs undergoing PBSCT. In a small group of patients undergoing HLA-identical sibling donor PBSCT, we were unable to show that the HTLp assay predicted for acute GVHD. 24 The variable success of the HTLp assay may be improved if the sensitivity of the assay could be increased. We hypothesized that the more potent antigen-presenting capacity of DCs would improve the sensitivity of the HTLp assay for detecting clinically significant host-reactive antigenic differences between HLA-identical sibling donor/ recipient pairs. Our understanding of the role and biology of DCs, the most potent antigen-presenting cells known, has improved considerably in recent times 25 as has our ability to generate useful numbers of these cells in vitro, 27, 34 and DCs have been shown to be able to generate HA-1-reactive T cells in vitro. 26 This knowledge now makes the testing of our hypothesis possible. To our knowledge, our study is currently the only published work that has assessed DCs as the stimulator cells in the HTLp assay.
We assessed, in parallel, the standard PBMC-based (standard) HTLp assay and DC-HTLp assay in 12 HLAidentical sibling donor/recipient pairs, of whom 11 were assessable for acute GVHD. The small sample numbers in our study make definitive conclusions impossible; however, our data suggest that the use of DCs improved the sensitivity of the HTLp assay. The DC-HTLp frequencies were statistically greater than the standard HTLp frequencies and, particularly, four of the seven patients who developed moderately severe to severe (index C-D) acute GVHD had significantly greater DC-HTLp frequencies compared to the frequencies as assessed by the standard HTLp assay; however, the DC-HTLp and standard HTLp frequencies for patients developing no to moderate (index 0-B) acute GVHD were similar (n ¼ 4). This is consistent with the hypothesis that host-reactive antigenic differences between the donor and recipient that are destined to induce significant acute GVHD are more readily identified when using potent antigen-presenting DCs as the stimulator cells in the HTLp assay. Perhaps, the remaining three donor/ recipient pairs in the group that developed index C-D acute GVHD with DC-HTLp frequencies that were not greater than the corresponding standard HTLp frequencies had host-reactive antigenic differences that were not expressed by hematopoietic cells. Hence, neither the standard or DCHTLp assays would be capable of detecting such differences not present on the stimulator cell population. Considerably larger numbers of donor/recipient pairs will be needed to test this hypothesis further.
During our experiments, we found it difficult to generate adequate numbers of monocyte-derived DCs from patient peripheral blood samples which, in turn, limited the number of DCs that could use as the stimulator cells in the DC-HTLp assay. Perhaps, the sensitivity of the assay could be further improved by using greater than the 12 500 DCs that were added to each well of this assay. Significantly larger numbers of DCs could be generated if larger numbers of patient PBMCs were obtained from larger volumes of blood (hundreds of milliliters) or from leukapheresed patient blood. Alternatively, DCs could be generated from G-CSF-mobilized patient PBSCs, 35 however, such maneuvers may not be possible or appropriate in routine clinical practice. In addition, DCs derived from different sources may have different properties, 34, 36 although this is yet to be fully elucidated.
The HTLp assay is labor-intensive and time-consuming, and the DC-HTLp assay is even more so because, as currently performed, the assay requires an additional 7-day culture to generate the DCs. This will make the assay unattractive to most stem cell transplant laboratories. A simpler approach may be to isolate peripheral blood DCs using one of the newer antibodies such as CMRF56, which can allow useful numbers of DCs to be obtained from peripheral blood in an overnight procedure. 37 Alternatively, DCs may be used in an elispot assay to determine the frequency of antigen-reactive T cells in the donor population. 38 This may be technically simpler and less timeconsuming.
There are seemingly many different types of DCs and several different stages of differentiation. 39 For a stimulatory assay such as the DC-HTLp assay, it would appear to be important to use mature DCs because immature DCs may actually inhibit the immune response and generate T-cell tolerance. 40, 41 The functional assay that is able to predict whether or not a particular patient will develop significant GVHD is still a worthy goal but, in more recent times, the assessment of mHA polymorphisms, 42, 43 cytokine gene polymorphisms [20] [21] [22] [23] and other gene polymorphisms 44 has proved an exciting new area of study. Several mHAs have been identified and some investigators have found an association between polymorphisms of these genes and GVHD, although other investigators have not shown this association. An increasing number of cytokines known to be important in the GVHD reaction, such as TNF-a, IL 10 and IL 1b, have had several polymorphisms identified. Some polymorphisms may allow an increased production of a particular cytokine in an immune response whereas other polymorphisms may allow a more modest production of cytokine despite similar inflammatory circumstances. Others gene polymorphisms, such as the gene encoding for the mannose-binding lectin, may alter the risk of GVHD by increasing or decreasing the susceptibility to infection. 44 This growing list of mHA, cytokine and other gene polymorphisms may help hematopoietic stem cell transplant physicians predict, with some degree of accuracy, whether or not a patient will develop severe GVHD. Although an understanding of these gene polymorphisms is of undoubted importance, the search for a clinically useful functional assay should not be abandoned just yet. A method to assess the clinical significance of a particular combination of gene polymorphisms in an individual donor/recipient pair would still be a useful clinical tool.
In conclusion, our study at least suggests that the DCHTLp assay may be better than the standard HTLp assay at detecting clinically significant host-reactive antigenic differences between HLA-identical sibling donor/recipient pairs, although in its current form, the DC-HTLp assay remains a difficult and labor-intensive assay.
